natgillin/translations-raw huggingface dataset:
I toksicitetsstudier med gentagne doser på mus, rotter og hunde var atazanavirrelaterede fund generelt begrænset til leveren og omfattede generelt minimale til milde forhøjelser af serum bilirubin og leverenzymer, hepatocellulær vacuolation og hypertrofi, og kun i hunmus hepatisk enkeltcellenekrose. 
In repeat-dose toxicity studies, conducted in mice, rats, and dogs, atazanavir-related findings were generally confined to the liver and included generally minimal to mild increases in serum bilirubin and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female mice only, hepatic singlecell necrosis.
Samtidig administration med REYATAZ/ritonavir kan potentielt reducere eller, mindre hyppigt, øge International Normaliseret Ratio (INR). 
Co-administration with REYATAZ/ritonavir has the potential to produce a decrease or, less often, an increase in INR (International Normalised Ratio).
Totalt fik 182 pædiatriske patienter (81 antiretroviral-naive og 101 antiretroviral-erfarne) i dette studie REYATAZ en gang dagligt (kapsler eller pulverformulering) med eller uden ritonavir, i kombination med to NRTI'er. 
Overall in this study, 182 paediatric patients (81 antiretroviral-naive and 101 antiretroviral-experienced) received once daily REYATAZ (capsule or powder formulation), with or without ritonavir, in combination with two NRTIs.
100 mg a Ritonavirkapsler, tabletter eller oral opløsning. 
100 mg a Ritonavir capsules, tablets or oral solution.
Atazanavirs minimumkoncentration var ca. 2 gange højere i post partum perioden sammenlignet med værdierne observeret historisk hos hiv-smittede ikke-gravide patienter. 
Atazanavir plasma trough concentrations were approximately 2-fold higher during the postpartum period when compared to those observed historically in HIV infected non-pregnant patients.
Atazanavir, det aktive stof i REYATAZ, udskilles i modermælk. 
Atazanavir, the active substance of REYATAZ, is excreted in human milk.
Den hele dosis REYATAZ oralt pulver (blandet med modermælkserstatning, væske eller føde) skal administreres inden for en time efter opblanding (i dette tidsrum kan blandingen opbevares ved stuetemperatur under 30°C). 
The entire dosage of REYATAZ oral powder (mixed in the liquid infant formula, beverage or food) is administered within one hour of preparation (the mixture can be left at room stored at temperatures not above 30°C during this period).
Din læge bør tage blodprøver før og under behandling med REYATAZ. 
Your doctor should do blood tests prior you start REYATAZ and during treatment.
100 mgd a De samme anbefalinger for voksne vedrørende tidspunkt og maksimal dosis af samtidigt administrerede protonpumpehæmmere og H2-receptorantagonister gælder også for pædiatriske patienter (se pkt. 
100 mgd a The same recommendations regarding the timing and maximum doses of concomitant proton pump inhibitors and H2receptor antagonists in adults also apply to paediatric patients (see section 4.5).
Produktresumé for ritonavir bør kontrolleres, inden behandling med REYATAZ og ritonavir initieres. 
The Summary of Product Characteristics for ritonavir must be consulted before initiation of therapy with REYATAZ and ritonavir.
Når REYATAZ/ritonavir administreres sammen med phenytoin eller phenobarbital, kan det være nødvendigt at justere dosis af phenytoin eller phenobarbital. 
When REYATAZ/ritonavir is co-administered with either phenytoin or phenobarbital, a dose adjustment of phenytoin or phenobarbital may be required.
Administration af REYATAZ og ritonavir sammen med et let eller et fedtrigt måltid nedsatte variationskoefficienten for AUC og Cmax med ca. 25% sammenlignet med i fastende tilstand. 
Administration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state.
Sildenafil, tadalafil, vardenafil Sildenafil, tadalafil og vardenafil metaboliseres af CYP3A4. 
Sildenafil, tadalafil, vardenafil Sildenafil, tadalafil, and vardenafil are metabolised by CYP3A4.
Brug af REYATAZ kan overvejes under graviditet, hvis den potentielle fordel opvejer den potentielle risiko. 
The use of REYATAZ may be considered during pregnancy only if the potential benefit justifies the potential risk.
REYATAZ oralt pulver indeholder sødestoffet aspartam. 
REYATAZ oral powder contains aspartame as a sweetening agent.
[95% KI]d 
[95% CI]
Afvigelsesestimate [95% KI] 
Difference estimatee [95% CI]
Der er vist effekt af REYATAZ/ritonavir i kombination med tenofovirdisoproxilfumarat hos behandlingserfarne patienter i det kliniske studie 045 og hos behandlingsnaive patienter i det kliniske studie 138 (se pkt. 
The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatmentexperienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1).
Tag ikke REYATAZ: hvis du er allergisk over for atazanavir eller et af de øvrige indholdsstoffer i REYATAZ (angivet i afsnit 6). 
Do not take REYATAZ if you are allergic to atazanavir or any of the other ingredients of this medicine (listed in section 6) if you have moderate to severe liver problems.
Den anbefalede pædiatriske dosis REYATAZ oralt pulver indeholder 3915,45 mg saccharose pr. 150 mg atazanavir, 5220,60 mg saccharose pr. 200 mg atazanavir, 6525,75 mg saccharose pr. 250 mg atazanavir og 7830,90 mg saccharose pr. 300 mg atazanavir. 
For the recommended paediatric dosage, REYATAZ oral powder contains 3915.45 mg sucrose per 150 mg atazanavir, 5220.60 mg sucrose per 200 mg atazanavir, 6525.75 mg sucrose per 250 mg atazanavir, and 7830.90 mg sucrose per 300 mg atazanavir.
Hjælpestoffer: indeholder lactose (se indlægsseddel for yderligere information) 4. 
LIST OF EXCIPIENTS Excipients: contains lactose (see leaflet for further information).
11 forsøgspersoner (13%) i gruppen med ikke-boostet REYATAZ og 6 forsøgspersoner (7%) i gruppen med REYATAZ + ritonavir oplevede virologisk rebound. 
Eleven subjects (13%) in the unboosted REYATAZ group and 6 (7%) in the REYATAZ + ritonavir group, had virologic rebound.
Autoimmune lidelser (såsom Graves sygdom og autoimmun hepatitis) er også set; tiden til udbrud er imidlertid mere variabel, og udbrud kan optræde mange måneder efter behandlingsstart (se pkt. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Andre markante, kliniske laboratoriemæssige abnormaliteter (grad 3 eller 4) rapporteret hos ≥2% af patienterne, der fik regimer indeholdende REYATAZ og én eller flere NRTIer omfattede: forhøjet kreatinkinase (7%), forhøjet alaninaminotransferase/serum-glutamin-pyrudrue transaminase (ALAT/SGPT) (5%), lav neutrofiltælling (5%), forhøjet aspartataminotransferase/serum-glutaminoxalsyretransaminase (ASAT/SGOT) (3%) og forhøjet lipase (3%). 
Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2% of patients receiving regimens containing REYATAZ and one or more NRTIs included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) (3%), and elevated lipase (3%).
Uge 48: 1,7% [-3,8%, 7,1%] Uge 96: 6,1% [0,3%, 12,0%] 
Week 48: 1.7% [-3.8%, 7.1%] Week 96: 6.1% [0.3%, 12.0%]
Valg af REYATAZ til behandlingserfarne voksne og pædiatriske patienter bør baseres på en individuel, viral resistenstest og patientens behandlingsanamnese (se pkt. 
The choice of REYATAZ in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1).
To procent af patienterne behandlet med REYATAZ oplevede samtidig grad 3-4 ALAT/ASAT og grad 3-4 forhøjelser af total bilirubin. 
Two percent of patients treated with REYATAZ experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations.
REYATAZ bør administreres 2 timer før eller 1 time efter antacida eller lægemidler med buffer. 
REYATAZ should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.
Vejledning for REYATAZ oralt pulver: 
Instructions for REYATAZ oral powder:
REYATAZ med ritonavir anbefales ikke til gravide, der både anvender tenofovirdisoproxil og en H2-receptorantagonist. 
It is not recommended to use REYATAZ with ritonavir for pregnant patients who are receiving both tenofovir disoproxil and an H2-receptor antagonist.
AUC ng•time/ml 
AUC ng•h/mL
b Se Beskrivelse af udvalgte bivirkninger. 
b See description of selected adverse reactions for more details.
≥ 200 celler/mm3 
≥ 200 cells/mm3
Samtidig administration af REYATAZ og ritonavir i doser over 100 mg én gang dagligt er ikke evalueret klinisk. 
Co-administration of REYATAZ with ritonavir at doses greater than 100 mg once daily has not been clinically evaluated.
Nedsat leverfunktion: Atazanavir metaboliseres og udskilles primært via leveren. 
Hepatic impairment: atazanavir is metabolised and eliminated primarily by the liver.
Proteasehæmmerresistens blev defineret som genotypisk resistens over for atazanavir eller de enkelte komponenter i den lokale NRTI-backbone baseret på kriterie 1) enhver type større mutationer: I50L, I84V, N88S og 2) ≥ 2 af følgende mindre eller krydsresistente mutationer: M46I/L, G48V, I54L/V/M/T/A, V82A/T/FI, L90M, V32I. 
Protease inhibitor resistance was defined as genotypic resistance to atazanavir or either component of the local NRTI backbone based on the criteria of 1) any major mutations: I50L, I84V, N88S and 2) ≥ 2 of the following minor or cross resistant mutations: M46I/L, G48V, I54L/V/M/T/A, V82A/T/FI, L90M, V32I.
Proteasehæmmere: Samtidig administration af REYATAZ/ritonavir og andre proteasehæmmere er ikke undersøgt, men forventes at øge eksponeringen for andre proteasehæmmere. 
Protease inhibitors: The co-administration of REYATAZ/ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors.
Faldet i AUC, Cmax, and Cmin var ikke mindre, når en øget dosis af REYATAZ/ritonavir (400/100 mg én gang dagligt) blev forskudt fra omeprazol med 12 timer. 
The decrease in AUC, Cmax, and Cmin was not mitigated when an increased dose of REYATAZ/ritonavir (400/100 mg once daily) was temporally separated from omeprazole by 12 hours.
REYATAZ 100 mg hårde kapsler REYATAZ 150 mg hårde kapsler REYATAZ 200 mg hårde kapsler REYATAZ 300 mg hårde kapsler 
REYATAZ 100 mg hard capsules REYATAZ 150 mg hard capsules REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules
produkter indeholdende grazoprevir, inklusive elbasvir/grazoprevir i fastdosis-kombination, og glecaprevir/pibrentasvir i fastdosis-kombination (bruges til behandling af kronisk hepatitis C infektion) 
grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)
a Antal patienter med parvise genotyper, der er klassificeret som virologisk svigt (hiv-RNA ≥ 400 kopier/ml). 
a Number of patients with paired genotypes classified as virological failures (HIV RNA ≥ 400 copies/ml).
REYATAZ/ritonavir-armen viste antiviral effekt svarende til lopinavir/ritonavir-armen (non-inferiør) vurderet ved andelen af patienter med hiv-RNA <50 kopier/ml ved uge 48 (tabel 5). 
The REYATAZ/ritonavir arm showed similar (non-inferior) antiviral efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV RNA < 50 copies/ml at week 48 (Table 5).
Hvert brev indeholder 30 breve. 
Each carton contains 30 sachets.
Kombinationer af REYATAZ og indinavir er ikke undersøgt, og samtidig administration af disse lægemidler kan ikke anbefales (se pkt. 
Combinations of REYATAZ and indinavir have not been studied and co-administration of these medicinal products is not recommended (see section 4.5).
REYATAZ har i kliniske studier (med eller uden ritonavir) vist sig at inducere dyslipidæmi i mindre udstrækning end andre sammenlignelige produkter, der indgik i studierne. 
In clinical studies, REYATAZ (with or without ritonavir) has been shown to induce dyslipidaemia to a lesser extent than comparators.
I det kliniske studie AI424-182 blev REYATAZ/ritonavir (300/100 mg eller 400/100 mg) administreret samtidig med zidovudin/lamivudin til 41 gravide kvinder i andet og tredje trimester. 
In clinical trial AI424-182 REYATAZ/ritonavir (300/100 mg or 400/100 mg) in combination with zidovudine/lamivudine was administered to 41 pregnant women during the second or third trimester.
Data vedrørende samtidig brug af parenteral midazolam og andre proteasehæmmere tyder på en mulig 34 gange stigning i midazolamplasmaniveauet. 
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels.
Brug af REYATAZ sammen med mad og drikke Det er vigtigt, at du tager REYATAZ sammen med mad (et måltid eller et større mellemmåltid), da dette hjælper kroppen med at optage medicinen. 
It is important that you take REYATAZ with food (a meal or a substantial snack) as this helps the body absorb the medicine.
Den oftest rapporterede laboratoriemæssige anormalitet hos patienter, der fik regimer indeholdende REYATAZ og én eller flere NRTIer, var forhøjet total bilirubin, primært indberettet som indirekte forhøjet [ukonjugeret] bilirubin (87% grad 1, 2, 3 eller 4). 
The most frequently reported laboratory abnormality in patients receiving regimens containing REYATAZ and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4).
Stop straks med at tage REYATAZ og tal med lægen, hvis du får alvorligt udslæt eller udslæt med influenzalignende symptomer, blærer, feber, forkølelsessår, muskel- eller ledsmerter, hævelse i ansigtet, øjenbetændelse, som forårsager røde øjne (konjunktivitis), smertefulde, varme eller røde knuder. 
Stop taking REYATAZ and talk to your doctor immediately if you develop a severe rash or a rash with flu-like illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling in the face, inflammation of the eye which causes redness (conjunctivitis), painful, warm, or red lumps (nodules).
Der er begrænset erfaring med akut human overdosering med REYATAZ. 
Human experience of acute overdose with REYATAZ is limited.
Blandt 1.151 patienter, der fik 400 mg atazanavir én gang dagligt, var 177 patienter samtidig inficeret med kronisk hepatitis B eller C, og blandt 655 patienter, der fik 300 mg atazanavir én gang dagligt med 100 mg ritonavir én gang dagligt, var 97 patienter samtidig inficeret med kronisk hepatitis B eller C. Samtidigt inficerede patienter havde større sandsynlighed for forhøjede levertransaminaser ved baseline end de, der ikke havde kronisk viral hepatitis. 
Patients co-infected with hepatitis B and/or hepatitis C virus Among 1,151 patients receiving atazanavir 400 mg once daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg once daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C. Co-infected patients were more likely to have baseline hepatic transaminase elevations than those without chronic viral hepatitis.
- - Øvrige indholdsstoffer: crospovidon, lactosemonohydrat og magnesiumstearat. 
- The other ingredients are crospovidone, lactose monohydrate, and magnesium stearate.
Der blev observeret M184V-substitution i revers transkriptase, som medfører resistens over for lamivudin og emtricitabin, hos 2 forsøgspersoner i gruppen med ikkeboostet REYATAZ og hos 1 forsøgsperson i REYATAZ + ritonavir-gruppen. 
The M184V substitution in reverse transcriptase, which confers resistance to lamivudine and emtricitabine, was detected in 2 subjects in the unboosted REYATAZ and 1 subject in the REYATAZ + ritonavir group.
Behandlingsnaiv REYATAZ pulver/ritonavir n=52 
Treatment-Naive REYATAZ Powder/ritonavir n=52
Disse lægemidler er nævnt i starten af afsnit 2 Brug ikke REYATAZ. 
These are listed under Do not take REYATAZ, at the start of Section 2.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) REYATAZ 50 mg oralt pulver 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION REYATAZ 50 mg oral powder
REYATAZ (uden ritonavir) er blevet undersøgt hos voksne forsøgspersoner med moderat til alvorligt nedsat leverfunktion (14 forsøgspersoner med Child-Pugh klasse B og 2 forsøgspersoner med Child-Pugh klasse C) efter en enkelt 400 mg dosis. 
REYATAZ (without ritonavir) has been studied in adult subjects with moderate-to-severe hepatic impairment (14 Child-Pugh Class B and 2 Child-Pugh Class C subjects) after a single 400 mg dose.
REYATAZ fås også som kapsler til voksne og børn på mindst 6 år, som vejer mindst 15 kg og som er i stand til at sluge kapsler. 
REYATAZ is also available in capsules for use in adults and children at least 6 years of age who weigh at least 15 kg and who are able to swallow the capsules.
Seponering af ritonavir fra det boostede REYATAZ-regime frarådes, men en dosis på 400 mg REYATAZ én gang dagligt sammen med føde kan overvejes hos voksne patienter under følgende kombinerede restriktive forhold: 
The withdrawal of ritonavir from the boosted regimen of REYATAZ is not recommended, but may be considered in adults patients at the dose of 400 mg once daily with food only under the following combined restrictive conditions:
Det bør sikres, at patienten spiser eller drikker al den pulverholdige modermælkserstatning, væske eller føde. 
It should be ensured that the patient eats or drinks all the infant formula, beverage or food that contains the powder.
Hjælpestof, som behandleren skal være opmærksom på: 63 mg aspartam; 1305,15 mg saccharose pr. brev (1,5 g oralt pulver). 
Excipient with known effect: 63 mg of aspartame; 1305.15 mg of sucrose per sachet (1.5 g oral powder).
Se doseringstabellen for den pågældende formulering (se produktresumeeet for REYATAZ kapsler). 
Consult the dosing table for the specific formulation (see Summary of Product Characteristics for REYATAZ capsules).
Samtidig administration af atazanavir/ritonavir og boceprevir medførte lavere atazanavir-eksponering, hvilket kan resultere i lavere effekt og manglende hiv-kontrol. 
Co-administration of atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir which may be associated with lower efficacy and loss of HIV control.
Noget medicin kan påvirkes af ritonavir, som tages sammen med REYATAZ. 
Some medicines may interact with ritonavir, a medicine that is taken with REYATAZ.
Brug af REYATAZ med ritonavir kan overvejes under graviditet, hvis den potentielle fordel opvejer den potentielle risiko. 
The use of REYATAZ with ritonavir may be considered during pregnancy only if the potential benefit justifies the potential risk.
Hver æske indeholder en HDPE-beholder (high density polyethylen) eller tre HDPE-beholdere (high density polyethylen) med børnesikret polypropylenlåg. 
Each carton contains one high-density polyethylene (HDPE) bottle or three high-density polyethylene (HDPE) bottles closed with child-resistant polypropylene closure.
Administration af REYATAZ og modermælkserstatning ved hjælp af en sutteflaske frarådes, da den fulde dosis muligivs ikke indgives. 
Administration of REYATAZ and infant formula using an infant bottle is not recommended because the full dose may not be delivered.
Blandt patienter, der fik 300 mg REYATAZ med 100 mg ritonavir, var frekvensen af gulsot 19%. 
Among patients receiving REYATAZ 300 mg with ritonavir 100 mg, the frequency of jaundice was 19%.
REYATAZ oralt pulver 1305,15 mg saccharose pr. brev. 
REYATAZ oral powder contains 1305.15 mg of sucrose per sachet.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) 
MARKETING AUTHORISATION NUMBER(S) Bottle pack
REYATAZ/ritonavir bør administreres 2 timer før eller 1 time efter antacida eller lægemidler med buffer. 
REYATAZ/ritonavir should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.
Blisterpakning: 30 hårde kapsler 
Blister pack: 30 hard capsules
En af nedenstående muligheder vælges for blanding og indgivelse sammen med modermælkserstatning, væske eller føde. 
The appropriate option listed below is chosen for mixing and administration with liquid infant formula, beverage or food.
Hvis du ved en fejltagelse har taget for mange REYATAZ-kapsler, skal du kontakte din hiv-læge eller nærmeste hospital og bede om råd. 
If you accidentally take more REYATAZ capsules than your doctor recommended, contact your HIV doctor at once or contact the nearest hospital for advice.
Gennem 48 ugers behandling var middelændringerne i hiv-RNA-niveauer fra baseline for REYATAZ + ritonavir og lopinavir + ritonavir sammenlignelige (ikke-inferior). 
Through 48 weeks of treatment, the mean changes from baseline in HIV RNA levels for REYATAZ + ritonavir and lopinavir + ritonavir were similar (non-inferior).
SÆRLIGE OPBEVARINGSBETINGELSER Beholderpakning: 
SPECIAL STORAGE CONDITIONS Bottle pack:
Hos hiv-inficerede patienter med svær immuninsufficiens kan der ved påbegyndelse af antiretroviral kombinationsbehandling (CART) opstå inflammatorisk reaktion på asymptomatiske eller residuale opportunistiske patogener, som kan forårsage alvorlige kliniske tilstande eller forværring af symptomer. 
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Hver beholder indeholder 60 hårde kapsler. 
Each bottle contains 60 hard capsules.
Til børn (mindst 3 måneder og med en kropsvægt på over 5 kg) vil barnets læge beslutte, hvilken dosis, der skal anvendes ud fra barnets vægt. 
For children (at least 3 months of age and weighing at least 5 kg), your child's doctor will decide the right dose based on your child's weight.
Baseret på disse data, og fordi ritonavir ikke forventes at have signifikant effekt på NRTI'ernes farmakokinetik, forventes samtidig administration af disse lægemidler og REYATAZ ikke at påvirke lægemidlernes eksponering signifikant. 
Based on these data and because ritonavir is not expected to have a significant impact on the pharmacokinetics of NRTIs, the co-administration of these medicinal products and REYATAZ is not expected to significantly alter the exposure of the co-administered medicinal products.
Der er ingen doseringsanbefalinger for REYATAZ til børn under 3 måneder. 
There are no dosing recommendations for REYATAZ in paediatric patients less than 3 months of age.
REYATAZ (uden ritonavir) er blevet undersøgt hos voksne patienter med alvorligt nedsat nyrefunktion (n=20), inklusive patienter i hæmodialyse, ved multiple doser på 400 mg en gang dagligt. 
REYATAZ (without ritonavir) has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Hvis det vurderes nødvendigt, bør samtidig administration kun ske efter individuel vurdering hos patienter med supprimeret hivvirusbelastning og med hivvirusstamme uden formodet resistens over for hivbehandlingen. 
This co-administration might be considered on a case by case basis if deemed necessary, in patients with suppressed HIV viral loads and with HIV viral strain without any suspected resistance to the HIV regimen.
Se "Brugsvejledning" i slutningen af indlægssedlen om, hvordan REYATAZ oralt pulver tilberedes og indgives. 
See the "Instructions for use" at the end of the package leaflet for how to prepare and give a dose of REYATAZ oral powder.